Teacher Retirement System of Texas Acquires 107,566 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Teacher Retirement System of Texas lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 32.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 442,579 shares of the biopharmaceutical company's stock after purchasing an additional 107,566 shares during the period. Teacher Retirement System of Texas' holdings in Gilead Sciences were worth $40,881,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC boosted its stake in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD stock traded up $1.15 during trading hours on Tuesday, reaching $107.89. The company had a trading volume of 8,444,141 shares, compared to its average volume of 6,795,009. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business has a fifty day moving average price of $104.01 and a 200-day moving average price of $94.15. The firm has a market cap of $134.36 billion, a PE ratio of 291.59, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of recent analyst reports. BMO Capital Markets upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Oppenheimer increased their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a report on Tuesday, March 4th. Wells Fargo & Company boosted their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Bank of America lifted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 302,785 shares of company stock worth $30,503,250 in the last quarter. Company insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.